Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
18°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Glaukos Corp
(NY:
GKOS
)
143.46
-0.54 (-0.38%)
Streaming Delayed Price
Updated: 3:41 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glaukos Corp
< Previous
1
2
3
4
5
6
7
8
Next >
These 2 Soaring Stocks Finished the Week Strong
July 14, 2023
Wall Street coasted into the close on Friday but still had a good week.
Via
The Motley Fool
Where Glaukos Stands With Analysts
July 14, 2023
Via
Benzinga
UnitedHealth, Elanco Animal Health And Other Big Stocks Moving Higher On Friday
July 14, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023
July 12, 2023
From
Glaukos Corporation
Via
Business Wire
Stifel Maintains Buy Rating for Glaukos: Here's What You Need To Know
June 26, 2023
Via
Benzinga
8 Analysts Have This to Say About Glaukos
June 26, 2023
Via
Benzinga
Analyst Expectations for Glaukos's Future
June 05, 2023
Via
Benzinga
Glaukos: Q1 Earnings Insights
May 03, 2023
Via
Benzinga
Expert Ratings for Glaukos
April 18, 2023
Via
Benzinga
Glaukos Poised for $1B in Sales by 2030: Piper Sandler Predicts With Stock Upgrade
June 07, 2023
Piper Sandler has upgraded Glaukos Corporation (NYSE: GKOS) to Overweight from a Neutral ra
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2023
June 07, 2023
Via
Benzinga
Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)
June 05, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the William Blair Growth Stock Conference
May 24, 2023
From
Glaukos Corporation
Via
Business Wire
Earnings Preview For Glaukos
February 21, 2023
Via
Benzinga
Analyst Expectations for Glaukos's Future
December 28, 2022
Via
Benzinga
Tyson Foods, PayPal And 3 Stocks To Watch Heading Into Monday
May 08, 2023
With US stock futures trading slightly lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Glaukos Announces FDA Acceptance of NDA Submission for iDose TR
May 05, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces First Quarter 2023 Financial Results
May 03, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting
May 01, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces the Release of its 2022 Sustainability Report
April 19, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3
April 12, 2023
From
Glaukos Corporation
Via
Business Wire
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It
March 09, 2023
Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease.
Via
Benzinga
Glaukos Submits New Drug Application to U.S. FDA for iDose TR
February 27, 2023
From
Glaukos Corporation
Via
Business Wire
NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday
February 23, 2023
Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose...
Via
Benzinga
Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results
February 22, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the Citi Healthcare Conference
February 15, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22
February 01, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability
January 10, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs
January 10, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 28, 2022
From
Glaukos Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
